Rare disease

Demyelination of neuron
#FDA #Muscular dystrophy #Paediatrics #Rare disease #SynaptixBio

Treatment for leukodystrophy could be “revolutionary”

The US Food and Drug Administration (FDA) has granted Rare Paediatric Disease (RPD) Designation to SynaptixBio’s drug candidate for TUBB4a leukodystrophy – a genetic and debilitating condition which mainly affects babies and young children.  RPDs are designed to encourage the development of new drugs with high unmet medical needs, including… Read More

#Editor's Choice #News #Regulatory

Luchen Li, wearing the sensor suit, and Professor Aldo Faisal.
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Clinical trials #Imperial College London #Movement disorders #Rare disease #Wearable tech

AI and wearable tech could speed up drug development

A multi-disciplinary team of researchers has developed a way to monitor the progression of movement disorders using motion capture technology and AI.   By combining human movement data gathered from wearable tech with a powerful new medical AI technology, the team were able to significantly increase the efficiency… Read More

#News

Woman having epileptic fit
#CHMP #epilepsy #Europe #Neuroscience #Rare disease

Treatment for severe form of epilepsy approved in Europe

UCB’s Fintepla (fenfluramine) oral solution has been recommended for marketing authorisation in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare, severe form of epilepsy.  The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion… Read More

#News #Regulatory

Human neurone
#Biosciences #Genetic diseases #Ion channels #Neurology #Neuroscience #Rare disease #Therapeutics

Ion channel modulators for ultra-rare genetic disorder 

Metrion Biosciences, a specialist ion channel contract research and drug discovery company, and The KCNC1 Foundation, a not-for-profit organisation focused on the development of a treatment for an ultra-rare genetic disorder, have entered a collaboration to progress a hit identification research project for small molecule modulators of the potassium… Read More

#News

#DNA #Gene mutation #Gene sequencing #Paediatrics #Rare disease

Researchers investigate genetic variants of paediatric diseases 

PacBio, developer of sequencing solutions, has announced its HiFi sequencing technology will be used in a pilot project for the Children’s Rare Disease Cohorts Initiative (CRDC) at Boston Children’s Hospital.   Boston Children’s Hospital researchers will use HiFi whole-genome sequencing (HiFi WGS) for the purpose of investigating genetic… Read More

#News

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

DDW Highlights podcast shares five new stories

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  ‘Teamwork makes the dream work’ this week, with the launch of… Read More

#News

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

This week in drug discovery (5-9 December)

News round-up for 5-9 December by DDW Digital Content Editor Diana Spencer. ‘Teamwork makes the dream work’ this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental disorders, lung cancer and rare paediatric diseases. The benefits of collaboration have also been… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Collaboration #Genetics / genomics #Neurodevelopmental disorders #Neurology #Precision medicine #Rare disease

Partnership hopes to advance precision drug development

A new partnership between industry and three rare disease foundations has formed with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders.  AI-driven genomics company Genomenon will partner with COMBINEDBrain, SynGAP Research Fund, and SLC-6A1 Connect and their pharma partners to deliver… Read More

#News

Child having physiotherapy
#Gene therapy #MHRA #Rare disease #UK

Gene therapy could ‘transform prognosis’ for AADC deficiency patients 

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) has received authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK.   Upstaza is the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency. It is also the first marketed gene therapy directly infused into the brain. The MHRA marketing… Read More

#News #Regulatory

#Cancer #Cancer research #Immuno-oncology #Immunotherapy #Molecular Biology #Oncology #Rare disease

Podcast: The next steps in the fight against cancer

This is the latest episode of the free DDW podcast, “The next steps in the fight against cancer”. It covers two articles written for Volume 22, Issue 4 – Fall 2021 of DDW. They are called “Accelerating research: the path forward for treating rare cancers” and “Inside combination… Read More

#News

#Clinical trials #Rare disease

Positive Phase I results for rare disease inhibitor 

Affibody’s licensee Rallybio Corporation has announced positive topline results from a Phase I single ascending dose study in healthy participants of RLYB116, a novel, potentially long-acting, subcutaneously administered inhibitor of complement factor 5, or C5, in development for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and generalised… Read More

#News

#Data #Diagnostics #Genetics / genomics #Healthcare #Public health #Rare disease #Whole genome sequencing

Personalising WGS doubles diagnosis of rare diseases 

A new study led by Medical Research Council-funded researchers from UCL has found that tailoring the analysis of whole genome sequencing to individual patients could double the diagnostic rates of rare diseases.  Context   In 2018, the UK’s department of health announced an NHS Genomic Medicine… Read More

#News

The European Medicines Agency building
#Accelerated assessment #Committee for Medicinal Products for Human Use #European Medicines Agency #Rare disease

EMA accelerates assessment of drug for rare disease APDS

A potential new treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) has been validated for scientific evaluation under an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP).  Pharming’s investigational drug leniolisib, a selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, will be evaluated as a therapy in adolescents… Read More

#News #Regulatory

#Covid-19 #Drug approvals #FDA #Influenza #Rare disease

This week in drug discovery (19-23 September)

News round-up for 19-23 September by DDW Editor Reece Armstrong An interesting week for clinical research and drug approvals, with rare diseases being a key focus for both the FDA and European Commission. The last week has seen data emerge on how Omicron infection could protect against influenza, how… Read More

#News

Blood cells
#Haemophilia #Interview #Novo Nordisk #Rare disease

Novo Nordisk: positivity for haemophilia treatment  

DDW Editor Reece Armstrong speaks to Stephanie Seremetis, Chief Medical Officer, Rare Blood Disorders at Novo Nordisk to get her response to the company's latest study results for its Mim8 antibody. Earlier this year, pharmaceutical company Novo Nordisk announced positive results from Phase I & II clinical trials investigating its… Read More

#Exclusive Content #Opinion